Cellestia ’s CB-103 in achieving complete response
22.06.2022
A case study shows contribution of Cellestia ’s CB-103 in achieving complete response in a relapse/refractor T-ALL patient...
News
BIOVERSYS SUCCESSFULLY COMPLETES PHASE I CLINICAL TRIALS OF BVL-GSK098
21.06.2022
BioVersys AG announces successful completion of Phase I clinical trials with BVL-GSK098...
BIOVERSYS ANNOUNCES CHF 24.2 MILLION FINANCING
08.06.2022
BioVersys AG announces successful first closing of CHF 24.2 million Series C financing to develop clinical pipeline of novel AMR...
Versant Ventures Launches Cimeio Therapeutics with $50 Million Series A
29.04.2022
Versant Ventures announced the debut of Cimeio Therapeutics, a biotechnology company developing a novel approach to ...
Ginkgo Bioworks Signs Definitive Agreement to Acquire FGen AG
18.03.2022
Ginkgo Bioworks, the leading horizontal platform for cell programming, today announced the entry into a definitive agreement to acquire...